CD28 and neoplasm: Conversely, CD80/CD86-targeted CAR-T (CTLA4-CAR), which comprises the extracellular and transmembrane portions of human CTLA4, the cytoplasmic region of human CD28, and the intracellular domains of human CD3z, was designed to destroy CD80/CD86-associated tumor cells in vitro and vivo.